A Vaccine for Multiple Sclerosis: Is it a Feasible Option?

Dennis N. Bourdette

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Multiple sclerosis is an immune-mediated disease of the CNS, and T cells appear to play a central role in its pathogenesis. In an animal model, T cells specific for myelin basic protein (MBP) induce a syndrome (experimental autoimmune encephalomyelitis) with symptoms similar to multiple sclerosis. This suggests that T cells specific for this protein may be pathogenic in multiple sclerosis. Anti-T cell vaccines that induce regulation of autoreactive T cells are effective treatments for experimental autoimmune encephalomyelitis. These anti-T cell vaccines include whole T cell vaccination, T cell receptor peptide immunisation, oral administration of myelin antigens and major histocompatibility complex (MHC) class II peptide immunisation. Preliminary experience in patients who have multiple sclerosis with the first 3 approaches suggests that anti-T cell vaccines represent feasible treatments for this disorder.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCNS Drugs
Issue number1
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'A Vaccine for Multiple Sclerosis: Is it a Feasible Option?'. Together they form a unique fingerprint.

Cite this